Claims for Patent: 9,486,451

Summary for Patent: 9,486,451

Title:	Abuse resistant pharmaceutical compositions
Abstract:	The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
Inventor(s):	Rekhi; Gurvinder S. (Suwanee, GA), Sidwell; Richard (Cumming, GA)
Assignee:	Recro Gainesville LLC (Gainesville, GA)
Application Number:	14/851,056
Patent Claims:	1. A method for the treatment of pain comprising: orally administering to a subject in need thereof a composition comprising a first population of beads and a second population of beads; wherein the first population of beads comprises hydrocodone or a pharmaceutically acceptable salt thereof, and wherein the first population of beads is substantially free of polyethylene oxide; and wherein the second population of beads comprises polyethylene oxide and a permeable or semi-permeable coating selected from the group consisting of an ammonio methacrylate copolymer, a methacrylic acid copolymer and a mixture thereof, and wherein the second population of beads is substantially free of any pharmaceutically active ingredient. 2. The method of claim 1, wherein said second population of beads further comprises povidone. 3. The method of claim 1, wherein the polyethylene oxide is present in particulate form. 4. The method of claim 1, wherein the pharmaceutically acceptable salt is hydrocodone bitartrate. 5. The method of claim 1, wherein the hydrocodone or pharmaceutically acceptable salt thereof is present in an amount of from 5 to 250 mg.